Supriya Lifescience Q3 FY26 Revenue Jumps 11.2% YoY to ₹206.44 Cr
Supriya Lifescience reported Q3 FY26 consolidated revenue of ₹206.44 crore, an 11.2% YoY increase. EBITDA was ₹72.08 crore and PAT was ₹49.68 crore. The anesthetic segment drove growth, with Latin America showing significant market share increase. Capacity utilization improved to 76%. The Ambernath formulation facility is set to launch in Q4 FY26.
The results show a healthy year-over-year growth, driven by key segments and geographic expansion, which is moderately positive for the company's outlook.
The company reported year-over-year growth in revenue and profit, along with improved capacity utilization and strategic expansion plans, indicating positive business performance.
Supriya Lifescience Ltd. announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors approved these results in a meeting held on February 09, 2026.
For the third quarter of FY26, the company reported a consolidated revenue of ₹206.44 crore, an increase of 11.2% compared to ₹185.65 crore in Q3 FY25. EBITDA stood at ₹72.08 crore, with an EBITDA margin of 34.9%, compared to ₹65.96 crore and a 35.5% margin in the same period last year. Profit After Tax (PAT) for Q3 FY26 was ₹49.68 crore, up from ₹46.78 crore in Q3 FY25, with the PAT margin at 24.1% versus 25.2%.
The anesthetic segment was the main growth driver for the nine months of FY26, contributing 54% of total revenues, up from 48% in 9M FY25. The vitamins segment's contribution increased from 11% to 12%. Growth was particularly strong in Latin America, with its market contribution rising to 24% from 21%, and North America increased to 6% from 3%. Europe remained the largest market, accounting for 36% of revenues, followed by Asia at 32%.
Capacity utilization improved to 76% in 9MFY26 from 70% in FY25. The company has acquired three land parcels near its existing manufacturing facilities to support future expansion. Mr. Satish Wagh, Executive Chairman, stated confidence in driving stronger growth, especially with the upcoming commercial launch of the Ambernath formulation facility in Q4 FY26 and deepening presence in regulated markets.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.